Stocks · News reference

8-K filing — CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)

Sep 25, 2026, 9:00 PMSEC EDGAR

Filed: 2026-09-25 AccNo: 0001477932-26-005805 Size: 163 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

CELZ

Source: edgar
Observed: Sep 25, 2026, 9:00 PM
Checked: Sep 25, 2026, 9:00 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaSep 25, 2026, 9:13 PMBenzinga Newsdesk
Creative Medical Technology Acquires 4M Additional BioDefense Stock For $200K Cash And 1M Shares, Raising Ownership To 80%
On September 24, 2026, Creative Medical Technology Holdings, Inc. (the "Company") entered into a Stock Purchase Agreement (the "Purchase Agreement") with Creative Acquisition Corp. ("CAC"),
CELZ
BenzingaSep 17, 2026, 1:06 PMBenzinga Newsdesk
Creative Medical Technology Announces Filing Of New US Provisional Patent Application To Expand IP Protection Surrounding Ultrasome, Its Proprietary Cell-Free Regenerative Medicine Platform
Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced the
CELZ
BenzingaAug 20, 2026, 6:24 PMBenzinga Newsdesk
Creative Medical shares are trading higher after the company announced that all patients have now been enrolled and treated across its FDA-cleared ADAPT clinical trial of CELZ-201 / Olastrocel, including the opioid expansion cohort.
CELZ

8-K filing — CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)

Connected Markets

Related Headlines

Creative Medical Technology Acquires 4M Additional BioDefense Stock For $200K Cash And 1M Shares, Raising Ownership To 80%

Creative Medical Technology Announces Filing Of New US Provisional Patent Application To Expand IP Protection Surrounding Ultrasome, Its Proprietary Cell-Free Regenerative Medicine Platform

Creative Medical shares are trading higher after the company announced that all patients have now been enrolled and treated across its FDA-cleared ADAPT clinical trial of CELZ-201 / Olastrocel, including the opioid expansion cohort.